asn 002

Gusacitinib (ASN-002) (ASN-002) is spleen tyrosine kinase (SYK) and janus kinase (JAK) inhibitor (IC50: 5-46 nM).

NPD-039 is an inhibitor of trypanosoma brucei phosphodiesterase B1 (TbrPDEB1).

Gusacitinib, also known as ASN-002 and EN-3351, is a potent dual inhibitor of SYK/JAK kinases. ASN002 showed strong antitumor activity in both hematological and solid tumor xenograft models. ASN002 strongly suppressed the SYK and JAK family kinase signaling pathways as measured in pLAT and pSTAT assays, respectively. When profiled in a panel of 178 cell lines, ASN002 showed strong anti-proliferative activity in many lymphoid/leukemia cell lines, including SU-DHL-6, SU-DHL-4, OCI-LY10, H929 and Pfeiffer.

Gusacitinib-d4 (ASN-002-d4) is the deuterium-labeled form of Gusacitinib. Gusacitinib (ASN-002) is an orally effective dual kinase inhibitor targeting SYK and JAK. It exhibits IC50 values of 5, 46, 4, 11, and 8 nM for SYK, JAK1, JAK2, JAK3, and TYK2, respectively. This compound effectively and rapidly suppresses key inflammatory pathways involved in the pathogenesis of atopic dermatitis. Gusacitinib is also used in research for conditions such as chronic hand eczema and basal cell carcinoma.